ArticleStem cell reports2022
Rapid tissue prototyping with micro-organospheres.
Article in Stem cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Modeling gliomas with organoids: Classification, fidelity, and guidelines for translational neuro-oncology.Neuro-oncology · 2026Review
- Harnessing human tumor organoids for cancer modeling and precision therapy.Protein & cell · 2026Review
- Integrated Microfluidic Platform for High-Throughput Generation of Intestinal Organoids in Hydrogel Droplets.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The application of experimental models for the drug discovery for digestive tumors.Molecular cancer · 2026Review
- From organoid culture to manufacturing: technologies for reproducible and scalable organoid production.npj biomedical innovations · 2026Review
- Re-evaluating breast malignant pleural effusion: toward evidence-based, precision-aligned care with organoids.Frontiers in bioengineering and biotechnology · 2026Article
- Lung cancer organoids for functional precision oncology: from disease modeling to clinical decision support.Frontiers in oncology · 2026Review
- Functional Precision Medicine Using MicroOrganoSpheres for Treatment Response Prediction in Advanced Colorectal Cancer.JCO precision oncology · 2026Article
- Review
- Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors.Inflammation and regeneration · 2025Review
- A microfluidic platform for culturing and high-content imaging of adult stem cell-derived organoids.Scientific reports · 2025Article
- Determination of Drug Sensitivity in Patient Derived Models of Breast Cancer by Multiparametric QPI.bioRxiv : the preprint server for biology · 2025Article
- Accelerated maturation of branched organoids confined in collagen droplets.Lab on a chip · 2025Article
- Strategies to Develop Regenerative Medicine Approaches for Olfactory Disorders.Clinical and experimental otorhinolaryngology · 2025Review
- Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems.Lab on a chip · 2025Review
- Advances and challenges in human 3D solid tumor models.Advanced functional materials · 2025Article
- Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges.Molecular cancer · 2025Review
- Cancer Organoids as reliable disease models to drive clinical development of novel therapies.Journal of experimental & clinical cancer research : CR · 2024Article
- Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.Advanced healthcare materials · 2024Review
- Next-Generation Modeling of Cancer Using Organoids.Cold Spring Harbor perspectives in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
Abstract
In vitro tissue models hold great promise for modeling diseases and drug responses. Here, we used emulsion microfluidics to form micro-organospheres (MOSs), which are droplet-encapsulated miniature three-dimensional (3D) tissue models that can be established rapidly from patient tissues or cells. MOSs retain key biological features and responses to chemo-, targeted, and radiation therapies compared with organoids. The small size and large surface-to-volume ratio of MOSs enable various applications including quantitative assessment of nutrient dependence, pathogen-host interaction for anti-viral drug screening, and a rapid potency assay for chimeric antigen receptor (CAR)-T therapy. An automated MOS imaging pipeline combined with machine learning overcomes plating variation, distinguishes tumorspheres from stroma, differentiates cytostatic versus cytotoxic drug effects, and captures resistant clones and heterogeneity in drug response. This pipeline is capable of robust assessments of drug response at individual-tumorsphere resolution and provides a rapid and high-throughput therapeutic profiling platform for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.